DIANT Pharma Inc

Startup

DIANT® Pharma, Inc. (DIANT) has introduced cutting-edge, advanced manufacturing platforms for nanoparticles such as mRNA-LNPs, liposomes and polymeric nanoparticles. DIANT’s technology is distinguished by its adaptability and seamless integration from nanoparticle generation to downstream operations as a closed system. This innovative framework delivers a multitude of advantages, including a more compact production footprint, decreased facility requirements, heightened scalability, reduced human intervention, elimination of holding times, and precise control over particle size distribution. DIANT’s innovative blueprint for continuous nanoparticle production is predicated on an end-to-end manufacturing platform tailored for nucleic acid–LNPs, placing an emphasis on a closed-loop system design and exhaustive process monitoring protocols. The proprietary DIANT® Jet technology serves as the key player for efficient LNP generation through controlled mixing methodologies, ensuring the production of LNPs featuring unwavering uniformity, scalability and exceptional particle characteristic across diverse applications.

DIANT’s mission is to transform the use of nanoparticles and LNPs in biopharmaceutical therapies by pioneering continuous and process-controlled manufacturing systems. We strive to enhance the speed, efficiency, and quality of nanoparticle processing, pushing to accelerate our client’s time to market and supporting the industries for the better.

website